GB Sciences Inc (GBLX)

[europa7]

Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days
https://www.sciencedirect.com/science/article/pii/S1549963417301405

Authors: Esther Berrocoso PhD, RaquelRey-Brea MS, Mercedes Fernández-Arévalo PhD, Juan Antonio Micó MD,PhD, Lucía Martín-Banderas PhD


GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain

Dr. Lucía Martín Banderas, Nanomedicine Researcher, Pharmacy and Technology Dept. at USE, Dr. Carlos Rios-Bedoya, Science Advisor to GB Sciences, Dr. Julián Martínez Fernández; Vice-Rector for Research at USE, Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, and Dr. Mercedes Fernández Arévalo, Nanomedicine Researcher, Pharmacy and Technology Dept at USE.

GB Sciences, Inc. (OTCQB: GBLX) has obtained the exclusive worldwide license to intellectual property covering a time-released cannabinoid formulation from the Universidad de Seville (“USE”), the Universidad de Cadiz (“UCA”), and the Centro de Investigación Biomédica en Red de Salud Mental (“CIBERSAM”).